10-QPeriod: Q3 FY2002

ABBOTT LABORATORIES Quarterly Report for Q3 Ended Sep 30, 2002

Filed November 5, 2002For Securities:ABT

Summary

Abbott Laboratories reported solid financial results for the third quarter and the first nine months of 2002. Net sales increased by 3.8% for the quarter and 8.5% for the nine-month period compared to the prior year, driven by growth in Pharmaceutical and International segments. Net earnings also showed significant improvement, with diluted earnings per share rising to $0.46 for the quarter from $0.40 in the prior year. The company's balance sheet remains strong, with increased working capital and robust operating cash flows. However, investors should note the ongoing legal proceedings, including an industry-wide investigation into the enteral nutritional business and issues related to the FDA consent decree for diagnostics manufacturing, which could materially impact future results.

Key Highlights

  • 1Net sales for the third quarter of 2002 increased by 3.8% to $4.34 billion compared to the same period in 2001.
  • 2For the first nine months of 2002, net sales grew by 8.5% to $12.85 billion, largely driven by the acquisition of BASF's pharmaceutical business and strong international performance.
  • 3Diluted earnings per share for the third quarter of 2002 were $0.46, an increase from $0.40 in the prior year's quarter.
  • 4Net earnings for the nine months ended September 30, 2002, significantly increased to $2.17 billion from $0.94 billion in the prior year.
  • 5Abbott maintained a strong cash flow from operating activities, generating $3.0 billion for the first nine months of 2002.
  • 6The company is facing ongoing legal proceedings, including an industry-wide investigation into its enteral nutritional business, which could have a material adverse effect on cash flows and operations.
  • 7A one-time pre-tax charge of $129 million was recorded in the second quarter of 2002 related to the U.S. FDA consent decree for diagnostics manufacturing, with ongoing EPS expected to be negatively impacted.

Frequently Asked Questions

Abbott Laboratories demonstrated strong performance in the third quarter of 2002. Net sales increased to $4.34 billion, up 3.8% from the prior year. Diluted earnings per share rose to $0.46, an improvement from $0.40 in the same period of 2001, indicating healthy profitability.

Sales growth was driven by the Pharmaceutical and International segments. The acquisition of BASF's pharmaceutical business in early 2001 continues to contribute significantly to the Pharmaceutical segment's performance. International sales also showed robust growth, reflecting the company's global reach.

Yes, Abbott is involved in several significant legal and regulatory matters. These include an industry-wide investigation by the U.S. Attorney's office into its enteral nutritional business, which could materially affect cash flows and operations. Additionally, the company recorded a charge related to a U.S. FDA consent decree concerning its diagnostics manufacturing operations, and ongoing earnings are expected to be impacted.

Abbott maintains a strong liquidity position, with net cash from operating activities totaling $3.0 billion for the first nine months of 2002. The company also has substantial available financial resources, including significant lines of credit, supporting its operations and potential future investments.